Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2019031603
pages 133-137

DNA Fingerprint Technology: Its Application in Detecting Pancreatic Cancer

Gayathri Chalikonda
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322
Neha Merchant
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322
Bhaskar V. K. S. Lakkakula
Sickle Cell Institute Chhattisgarh, Raipur, India
Ganji Purnachandra Nagaraju
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322


Pancreatic cancer (PC) is one of the most lethal forms of cancers, ranking as the third highest cause of malignancies and fatalities. Approximately 88% of patients diagnosed with PC are older than 55 yr. Due to PC's vague symptoms, patients typically visit their doctor only when they experience symptoms of extreme pain and/or after their bile ducts have blocked. This produces symptoms including darkly colored urine, jaundice, and light-colored stools. At this point in the progression of the disease, the tumor has already metastasized. Early detection of PC is critical and justifies the need for innovative techniques to efficiently aid in this process. Current research involves screening different aspects of the disease, imaging techniques, and evaluating blood, urine, cell, and saliva biomarkers. We propose that forensic DNA fingerprinting can be used to establish the role of genetics in PC, and we describe disease inheritance patterns so that relatives can understand the likelihood of developing this lethal malignancy.


  1. van Oorschot RA, Ballantyne KN, Mitchell RJ. Forensic trace DNA: A review. Invest Gen. 2010 Dec;1(1):14.

  2. Kenner BJ, Go VL, Chari ST, Goldberg AE, Rothschild LJ. Early detection of pancreatic cancer: The role of industry in the development of biomarkers. Pancreas. 2017 Nov;46(10):1238.

  3. Lo W, Morris MC, Ahmad SA, Patel SH. Screening patients at high risk for pancreatic cancer: Is it time for a paradigm shift? J Surg Oncol. 2019. doi: 10.1002/ jso.25616.

  4. Pizzato M, Turati F, Rosato V, La Vecchia C. Exploring the link between diabetes and pancreatic cancer. Exp Rev Anticancer Ther. 2019:1-7. doi: 10.1080/14737140.2019.1642109.

  5. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: Challenges and new developments. Biomarkers Med. 2012 Oct;6(5):597-612.

  6. Nagaraju GP, Reddy BM. Exploring pancreatic metabolism and malignancy. Singapore: Springer; 2019. In press. doi:10.1007/978-981-32-9393-9.

  7. Panneerchelvam S, Norazmi MN. Forensic DNA profiling and database. Malaysian J Med Sci. 2003 Jul;10(2):20.

  8. Saad R. Discovery, development, and current applications of DNA identity testing. Proc Bayl Univ Med Cent. 2005;18:130-3.

  9. Arenas M, Pereira F, Oliveira M, Pinto N, Lopes AM, Gomes V, Carracedo A, Amorim A. Forensic genetics and genomics: Much more than just a human affair. PLoS Genet. 2017 Sep 21;13(9):e1006960.

  10. Roewer L. DNA fingerprinting in forensics: Past, present, future. Invest Genet. 2013 Dec;4(1):22.

  11. Butler JM. The future of forensic DNA analysis. Philos Trans R Soc Lond B Biol Sci. 2015;370(1674):1-10.

  12. Bhatti S, Aslam Khan M, Abbas S, Attimonelli M, Gonzalez GR, Aydin HH, de Souza EM. Problems in mitochondrial DNA forensics: While interpreting length heteroplasmy conundrum of various Sindhi and Baluchi ethnic groups of Pakistan. Mitochon DNA. Part A. 2018 May 19;29(4):501-10.

  13. Lutz S, Weisser HJ, Meier V, Amberg R. Significance of mitochondrial DNA for forensic stain analysis, identification and forensic lineage determination. Archiv Kriminologie. 2000;206(1-2):50-8.

  14. Hirano M. Mitochondrial neurogastrointestinal encephalopathy disease. GeneReviews [Internet]. Seattle, WA: University of Washington; 2016. Available from:

  15. Ciafaloni E, Ricci E, Shanske SM, Moraes CT, Silvestri G, Hirano M, Simonetti S, Angelini C, Donati MA, Garcia C, Martinuzzi A. MELAS: Clinical features, biochemistry, and molecular genetics. Ann Neurol. 1992 Apr;31(4):391-8.

  16. Salas A, Lareu MV, Carracedo A. Heteroplasmy in mtDNA and the weight of evidence in forensic mtDNA analysis: A case report. Int J Legal Med. 2001;114:186-90.

  17. Melton T, Nelson K. Forensic mitochondrial DNA analysis: Two years of commercial casework experience in the United States. Croat Med J. 2001;42:298-303.

  18. Pietrasz D, Pecuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, Laurent-Puig P. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017 Jan 1;23(1):116-23.

  19. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015 Jan 1;61(1):112-23.

  20. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. 31. Liquid biopsy: Monitoring cancer. Genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472.

  21. Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. "Liquid biopsy": ctDNA detection with great potential 33 and challenges. Ann Trans Med. 2015 Sep;3(16):235.

  22. Brock G, Castellanos-Rizaldos E, Hu L, Coticchia C, Skog J. Liquid biopsy for cancer screening, patient stratification and monitoring. Trans Cancer Res. 2015 Jun 18;4(3):280-90.

  23. Ilie M, Hofman P. Pros: Can tissue biopsy be replaced by liquid biopsy?. Trans Lung Cancer Res. 2016 Aug;5(4):420.

  24. Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner 35. M, Brand RE. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci. 2017 Sep 19;114(38):10202-7.

  25. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017 Sep;14(9):531.

  26. Kim EH, Andriole GL. Prostate-specific antigen-based screening: Controversy and guidelines. BMC Med. 2015 Dec;13(1):61.

  27. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: A systematic review 38. of programs in the prostate specific antigen era. J Urol. 2006 Aug 1;176(2):439-49.

  28. Hood L, Rowen L. The Human Genome Project: Big science transforms biology and medicine. Genome Med. 2013;5:79.

  29. Amundadottir LT. Pancreatic cancer genetics. Int J Bio Sci. 2016;12(3):314-25.

  30. Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, 40. Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018 Jun 19;319(23):2401-9.

  31. Page K, Graham EA. Cancer and forensic microsatellites. Forens Sci Med Pathol. 2008;4:60-6.

  32. Peltomaki P. DNA mismatch repair and cancer. Mutat Res. 2001;488:77-85.

  33. Pelotti S, Ceccardi S, Alu M, Lugaresi F, Trane R, Falconi M, Bini C, Cicognani A. Cancerous tissues in forensic genetic analysis. Gen Testing. 2007 Dec 1;11(4):397-400.

  34. Chifenti B, Morelli M, Zavaglia M, Coviello DA, Guerneri S, Santucci A, Paffetti A, Masetti M, Locci MT, Bertacca G, Capodanno A. Establishment and characterization of 4 new human pancreatic cancer cell lines: Evidences of different tumor phenotypes. Pancreas. 2009 Mar 1;38(2):184-96.

  35. Claerhout S, Vandenbosch M, Nivelle K, Gruyters L, Peeters A, Larmuseau MH, Decorte R. Determining Y-STR mutation rates in deep-routing genealogies: Identification of haplogroup differences. Forens Sci Int Genet. 2018 May 1;34:1-10.

  36. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.

  37. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003 Feb 5;95(3):214-21.

  38. Tothill IE. Biosensors for cancer markers diagnosis. Semin Cell Dev Biol. 2009 Feb;20(1):55-62.

  39. Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015 Mar 1;148(3):556-64.

  40. Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, Delle Fave G, Del Chiaro M. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastro Endoscopy. 2015 Jul 25;7(9):833.

Articles with similar content:

Genetically Modified Aedes aegypti to Control Dengue: A Review
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Muhammad Masoud, Muhammad Qsim, Ijaz Rasul, Namrah Noor, Usman Ali Ashfaq, Muhammad Zubair Yousaf, Azfar Hussain
Commentary on Lynch Syndrome and Related Familial Colorectal Cancers
Critical Reviews™ in Oncogenesis, Vol.14, 2008, issue 1
Stephen J. Lanspa, Henry T. Lynch
An Evidence-Based Algorithmic Approach to Cervical Spinal Disorders
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.13, 2001, issue 4
Larry Chou, Zacharia Isaac, Curtis W. Slipman, David W. Chow, David A. Lenrow, Mark Ellen, Edward J. Vresilovic, Jr.
Tumor Plasticity Interferes with Anti-Tumor Immunity
Critical Reviews™ in Immunology, Vol.34, 2014, issue 2
Andres Tittarelli, Salem Chouaib, Jean Paul Thiery, Bassam Janji, Alexander Eggermont
Hepatocellular Carcinoma and Possible Chemical and Biological Causes: A Review
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Belmar Kocer-Gumusel, Ming-Wei Chao, Didem Oral, Pinar Erkekoglu